Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™Greenhouse trial results published jointly with USDA-ARS demonstrate 76-98% reduction in aflatoxin contamination in transgenic corn expressing the BioCypher-designed peptide AGM182
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & CommercializationAgricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery ConferenceWoodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the 3rd Annual DealFlow Discovery Conference, taking place January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey.
Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection TechnologiesWoodland, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced it has entered into a formal teaming agreement with Tuskegee University, a premier research institution renowned for innovation in agricultural science and biotechnology. The collaboration seeks to fast-track next-generation peptide technologies through advances in biological manufacturing and the discovery of novel sequences that enhance crop protection, resilience, and nutrient performance.
Genvor Announces Issuance of New U.S. Patent for Corn with Antifungal PeptideWoodland, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, announced today the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,458,684, titled “Transgenic Corn with Antifungal Peptide AGM182.” The patent, co-assigned to Genvor Inc. and the United States Department of Agriculture (USDA), covers transgenic corn expressing the antifungal peptide AGM182, designed to combat fungal infections in maize.
Genvor Restores Trading Status and Expands Global Collaborative Research NetworkWoodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQB trading status on OTC Markets, positioning the company to accelerate capital formation as it scales field trials across multiple continents and crop applications. The reinstatement reflects the company’s ongoing commitment to compliance, transparency, and long-term growth as it advances four active research and development collaborations spanning three continents.
